Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
OMX Ventures
AddedFeb 15, 2024
UpdatedJun 28, 2026
OMX Ventures

OMX Ventures

Operating

OMX Ventures: A VC firm investing in the intersection of biology and computing.

Location
Lincolnshire, IL, US
Founded
2020
Firm
Compare
Portfolio
Employees
Website

OMX Ventures is a venture capital firm that focuses on investing at the intersection of biology and computing. The firm typically participates in Seed, Series A, Series B, and Series D funding rounds, supporting innovative startups with investments that span various stages of development. OMX Ventures is dedicated to backing companies that leverage the convergence of biological sciences and computational technologies to drive transformative advancements.

Notable portfolio companies include Aperiam Bio, Delix Therapeutics, Finch Therapeutics, Freya Biosciences, Glyphic Biotechnologies, Matterworks, Mythic Therapeutics, Replay, and VedaBio. The firm prides itself on its deep expertise in both biology and computing, offering strategic guidance and support to its portfolio companies. Key partners and decision-makers at OMX Ventures bring a wealth of experience from leading institutions and successful ventures in the biotech and tech industries, ensuring that their investments are well-positioned for growth and innovation.

OMX Ventures - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments10
Current Portfolio Count9
Total Portfolio Exits0

Top Investment Stages

Seed4 (40.0%)
Series A4 (40.0%)
Series B1 (10.0%)
Series D1 (10.0%)

Stage Mix

Seed 40%Series A 40%Series B 10%Series D 10%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Freya Biosciences logo

Freya Biosciences

Aperiam Bio logo

Aperiam Bio

VedaBio logo

VedaBio

Replay logo

Replay

Mythic Therapeutics logo

Mythic Therapeutics

Delix Therapeutics logo

Delix Therapeutics

Glyphic Biotechnologies logo

Glyphic Biotechnologies

Matterworks logo

Matterworks

Finch Therapeutics logo

Finch Therapeutics

OMX Ventures - Similar Investment Firms

Omers Ventures logo

Omers Ventures

omersventures.com

Oxantium Ventures logo

Oxantium Ventures

oxantium.com

Oxford Bioscience Partners logo

Oxford Bioscience Partners

kilbycream.com

OVP Venture Partners logo

OVP Venture Partners

Oyster Ventures logo

Oyster Ventures

oyster.vc

Illumina Ventures logo

Illumina Ventures

Bioluminescence Ventures logo

Bioluminescence Ventures

Omega Venture Partners logo

Omega Venture Partners

omegavp.com

Outsized Ventures logo

Outsized Ventures

EVX Ventures logo

EVX Ventures

evx.ventures

Endpoint Ventures logo

Endpoint Ventures

endpoint.vc

First In Ventures logo

First In Ventures

Ocama Partners logo

Ocama Partners

ocamapartners.com

Dcvc Bio logo

Dcvc Bio

dcvc.com

Bioventures Investors logo

Bioventures Investors

OMX Ventures - Classification

Also Known As
  • OMX Ventures, LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions